Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Myers
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 1.72
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.69
Financials
Net Income
$-4.87MEBITDA
$-4.90MFree Cash Flow
$-5.77MEPS (diluted)
$-0.97Shares Outstanding (diluted)
5.04M+1143256.2%Operating Expenses
$4.92MCash & Debt
$10.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-15.80M | $-14.80 |
| 2024 | $0.00 | $-8.96M | $-2352.81 |
| 2023 | $0.00 | $-8.69M | $-11781.00 |
| 2022 | $0.00 | $-9.38M | $-11.42 |
| 2021 | $0.00 | $-21.46M | $-2490.26 |
| 2020 | $0.00 | $-2.10M | $-1290.96 |
| 2019 | $0.00 | $-1.56M | $-16307.00 |
| 2018 | $-280.0K | $15.32M | $-158862.00 |
| 2017 | $0.00 | $10.17M | $-257489.00 |
| 2016 | $-280.0K | $15.32M | $-160847.00 |
| 2015 | $0.00 | $-2.62M | $-1.23 |
Valuation
QNRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+37.50%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·16d ago·Positive
Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW episode. ASHBURN, Va.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient's Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with QRX003, Patient's Skin Remains Fully Clear and Pruritu
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
View source ↗ - Newsglobenewswire.com·86d ago·Negative
…uoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds, includin…
View source ↗ - Newsglobenewswire.com·100d ago·Negative
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – Receives U.S. Notice of Allowance for a Patent Covering a Combination Treatment for Netherton Syndrome – Submits First-Ever IND for Peeling Skin Syndrome; FDA Clearance Received Subseque
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.94 per share
Typical surprise -3.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.97 vs $-1.88beat
- Fri, Aug 14$-1.90 vs $-1.83miss
- Thu, May 7$-1.77 vs $-1.80beat
- Thu, Mar 26$-14.80 vs $-6.42miss
- Thu, Nov 6$-6.71 vs $-6.36miss
- Thu, Aug 7$-6.28 vs $-6.83beat
Estimates and results for QNRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QNRX officers and directors.
- Bought
- $3.1m
- Sold
- $217
38 trades
1 trade
- Carter Denise P.bought
- Carter Denise P.bought
- Myers Michaelbought
- Myers Michaelbought
- Lawlor Sally Bridgetbought
- Lawlor Sally Bridgetbought
- Culverwell Anthony Jamesbought
- Culverwell Anthony Jamesbought
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in QNRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
